Advertisement
Journal Home
Search for
 
Cover Image

Visit the JACI on Facebook

Impact

See How The JACI's Impact Factor Compares

Current Issue

February 2010 | Vol. 125, No. 2

Download Table of Contents

2010 Annual Meeting Abstracts

JACI Journal Club blog
Each month, selected JACI articles are explored in greater depth at www.jaci-online.blogspot.com. This month's selections:
• Li et al., Mathais et al., and Wu et al. present three reports of genome-wide association studies. JACI Associate Editor Donata Vercelli, in an accompanying editorial, discusses just what we can learn from these studies.
• Massanari et al. investigate the effect that pre-treatment with omalizumab has on the tolerance of specific immunotherapy in patients with allergic asthma.


News Beyond Our Pages blog
A supplement to our monthly News Beyond Our Pages section, our section editors Marc Rothenberg and Jean Bousquet bring you news, recently published articles from other journals, and ongoing research and trends in the allergy/immunology community. Visit www.jaci-nbop.blogspot.com.

Featured Article of the Week:


Leukotriene receptor antagonists inhibit secretion, even from extracellular eosinophil granules
Montelukast inhibits stimulatory actions of cysteinyl leukotrienes, as currently recognized by principally blocking a single cysteinyl leukotriene receptor (CysLT1R) expressed on surface membranes of cells, including eosinophils, a class of leukocytes associated with allergic diseases. In eosinophil-associated diseases lysis of eosinophils releases free, intact, membranebound granules; however, the functional capacities of these extracellular eosinophil granules and their pertinence to allergic diseases have never been defined. Neves et al (p 477), writing in this issue of the Journal, document that cell-free human eosinophil granules express on their granule surface membranes ligand-binding domains for 2 cysteinyl leukotriene receptors and a purinergic receptor responsive to cysteinyl leukotrienes and demonstrate that cysteinyl leukotrienes, including those formed extracellularly, stimulate isolated eosinophil granules to secrete eosinophil cationic protein. Moreover, montelukast and a purinergic receptor antagonist that blocks the same receptor as does clopidogrel inhibited secretion of eosinophil cationic protein from eosinophil granules. These findings not only demonstrate that extracellular eosinophil granules in sites of allergic inflammation are secretion-competent organelles but also indicate that therapeutics, such as montelukast, might be beneficial not solely by acting on a single receptor (CysLT1R) expressed on intact cells but also by acting more broadly on other cysteinyl leukotriene receptors, including those expressed on cell-free eosinophil granules in sites of allergic inflammation. Read the full article here.

View all Featured Articles for this month.

Special Features:

Shared Science. In collaboration with other journals and their sponsoring societies, the JACI is pleased to offer free online access to selected articles.
JACI in the News. View coverage of JACI articles in news outlets from around the world.
Article Collections. Browse articles from several of the JACI's ongoing series of review and feature articles.
Most-Accessed Articles. What JACI articles are other people interested in? View the latest list of most-accessed articles from the past few months.
Advances in Allergy and Immunology. Our annual series reviewing the best and most exciting research reported in JACI during the previous year.
News Beyond Our Pages. Drs. Marc Rothenberg and Jean Bousquet bring you the latest in news, ideas, and research for the allergist-immunologist.


The Journal of Allergy and Clinical Immunology is published by Elsevier for the American Academy of Allergy, Asthma & Immunology.

SUBSCRIPTION/ACCESS SERVICES

Already have a username and password? Click here to log in.
First-time User? Create an account here.
Institutional subscribers: Click here to access your journal subscription
AAAAI members: Click here for access.
Subscribe to the journal now!
Free Trial Issue